HomeCompareSNNAF vs PFE

SNNAF vs PFE: Dividend Comparison 2026

SNNAF yields 3159.56% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNNAF wins by $745463794374.88M in total portfolio value
10 years
SNNAF
SNNAF
● Live price
3159.56%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$745463794374.93M
Annual income
$701,771,275,818,661,000.00
Full SNNAF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SNNAF vs PFE

📍 SNNAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNNAFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNNAF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNNAF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNNAF
Annual income on $10K today (after 15% tax)
$268,562.40/yr
After 10yr DRIP, annual income (after tax)
$596,505,584,445,861,900.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SNNAF beats the other by $596,505,584,445,839,600.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNNAF + PFE for your $10,000?

SNNAF: 50%PFE: 50%
100% PFE50/50100% SNNAF
Portfolio after 10yr
$372731897187.49M
Annual income
$350,885,637,909,343,600.00/yr
Blended yield
94.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SNNAF
No analyst data
Altman Z
3.3
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNNAF buys
0
PFE buys
0
No recent congressional trades found for SNNAF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNNAFPFE
Forward yield3159.56%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$745463794374.93M$49.6K
Annual income after 10y$701,771,275,818,661,000.00$26,258.71
Total dividends collected$742451097055.10M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SNNAF vs PFE ($10,000, DRIP)

YearSNNAF PortfolioSNNAF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$326,656$315,955.77$9,153$693.39+$317.5KSNNAF
2$9,995,201$9,645,679.71$8,593$849.25+$9.99MSNNAF
3$286,530,442$275,835,576.03$8,336$1,066.78+$286.52MSNNAF
4$7,696,609,407$7,390,021,834.62$8,437$1,384.80+$7696.60MSNNAF
5$193,755,323,586$185,519,951,520.47$9,013$1,875.40+$193755.31MSNNAF
6$4,572,084,955,106$4,364,766,758,868.91$10,306$2,680.72+$4572084.94MSNNAF
7$101,150,369,652,779$96,258,238,750,815.20$12,820$4,101.38+$101150369.64MSNNAF
8$2,098,479,445,063,981$1,990,248,549,535,507.50$17,673$6,826.70+$2098479445.05MSNNAF
9$40,834,129,491,836,980$38,588,756,485,618,510.00$27,543$12,591.86+$40834129491.81MSNNAF
10$745,463,794,374,926,600$701,771,275,818,661,000.00$49,560$26,258.71+$745463794374.88MSNNAF

SNNAF vs PFE: Complete Analysis 2026

SNNAFStock

Sienna Resources Inc. engages in the identification, acquisition, and exploration of mineral properties in Canada, Sweden, Finland, Norway, and the United States. The company primarily explores for platinum, palladium, nickel, copper, cobalt, and lithium deposits. It holds interests in the Slättberg project located in southern Sweden. The company also holds interests in Kuusamo PGE-Ni-Cu-Co project, Finland; Clayton Valley Deep Basin Lithium Brine project, North America; and Marathon North Platinum-Palladium Property covering an area of approximately 16,500 acres and located in Northern Ontario, Canada. In addition, it holds interest in the Blue Clay lithium project covering an area of approximately 2,950 acres located in the Clayton Valley of Nevada; and White Gold project located in Yukon, Canada. The company was formerly known as Habanero Resources Inc. and changed its name to Sienna Resources Inc. in January 2014. Sienna Resources Inc. was incorporated in 1983 and is headquartered in Vancouver, Canada.

Full SNNAF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SNNAF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNNAF vs SCHDSNNAF vs JEPISNNAF vs OSNNAF vs KOSNNAF vs MAINSNNAF vs JNJSNNAF vs MRKSNNAF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.